Investors looking to gain exposure to medical breakthroughs often face a choice between a narrow biotechnology focus or broader healthcare sector exposure. 

Brokers from Risance dive into how a concentrated biotech-focused fund compares against a diversified, low-cost healthcare fund across cost, volatility, and long-term performance.

Two Very Different Approaches to Healthcare

The two funds represent very different approaches to investing in the healthcare sector. One fund focuses on targeted exposure to the biotechnology industry, aiming to capture growth opportunities from innovative drug development and medical breakthroughs. 

In contrast, the other provides broad, low-cost diversification across the wider healthcare market, covering multiple industries such as pharmaceuticals, medical devices, healthcare services, and biotechnology.

The diversified fund holds 411 stocks across nearly the entire healthcare sector, reducing reliance on any single industry segment or company. 

Meanwhile, the more specialised fund maintains a concentrated portfolio of just 25 biotech-focused holdings, offering investors greater exposure to the potential upside of biotech innovation but also increasing sensitivity to sector-specific risks. This creates a key choice between broader stability and focused growth potential.

Cost and Yield Favor the Broader Fund

The two funds show a clear difference in cost efficiency and income generation. The broad healthcare fund offers a lower expense ratio of 0.09%, compared with 0.35% for the biotech-focused fund, giving investors a meaningful cost advantage over the long term. It also provides a higher dividend yield of 1.6%, compared with just 0.5% from the more concentrated biotech option.

These differences highlight the contrast between the two strategies: the diversified fund prioritizes lower costs and steady income, while the biotech-focused fund emphasizes targeted exposure to a higher-growth segment of healthcare. 

For investors seeking consistent returns and reduced expenses, the broader fund may offer greater efficiency, while those willing to accept more volatility may prefer the potential upside of biotech innovation.

Performance Has Clearly Favored Diversification

The broader healthcare strategy has produced stronger results over extended periods, despite the biotech fund showing a higher one-year return. Over the trailing 12 months, the diversified fund gained 22.7%, compared with 25.5% for the concentrated biotech fund. 

However, the longer-term comparison favours the broader approach. A $1,000 investment in the diversified fund grew to approximately $1,278 over five years, outperforming the $1,004 generated by the biotech-focused fund.

These results suggest that broader sector diversification has provided more consistent long-term performance, helping reduce the impact of biotech-specific volatility. 

While concentrated biotech exposure can deliver stronger short-term gains during favourable periods, the diversified healthcare fund has demonstrated greater resilience and more reliable wealth-building potential over a longer investment horizon.

Volatility Tells an Important Story Too

The two funds show a significant difference in risk exposure, with the concentrated biotech fund experiencing much greater volatility. Over the past five years, the biotech-focused fund recorded a maximum drawdown of 39.9%, compared with only 17.7% for the diversified healthcare fund.

This wider decline reflects the higher uncertainty associated with biotech investments, where stock prices can react sharply to developments such as clinical trial results, regulatory decisions, and drug approval outcomes. 

In contrast, the broader healthcare fund benefits from exposure across multiple industries, helping reduce the impact of weakness in any single segment. The difference highlights the trade-off between higher potential growth from specialised biotech exposure and the stability provided by broader healthcare diversification.

What’s Actually Inside Each Portfolio

The two funds differ in their portfolio concentration despite both focusing on healthcare-related companies. The diversified healthcare fund holds 411 stocks, with its largest positions in Eli Lilly (14.19%), Johnson & Johnson (8.89%), and AbbVie (6.56%). 

Although the portfolio provides broad sector exposure, these three holdings alone represent around 30% of total assets, giving major healthcare leaders a meaningful influence on performance.

Meanwhile, the biotech-focused fund takes a more concentrated approach, with its largest allocations in Amgen (15.58%), Gilead Sciences (13.19%), and Vertex Pharmaceuticals (8.64%). These top holdings account for a significant portion of the fund, reflecting its focus on established biotechnology companies. This structure provides greater exposure to biotech growth opportunities but also increases sensitivity to company-specific developments and industry volatility.

Which Fund Fits Which Type of Investor

The diversified healthcare fund has demonstrated stronger long-term performance, delivering a 159% total return over the past decade with a 10.0% compound annual growth rate. Its results reflect the benefits of low expenses, broad sector exposure, consistent performance, and a reliable dividend yield.

In comparison, the biotech-focused fund generated a 10-year total return of 87%, with a 6.5% compound annual growth rate, highlighting the impact of its higher costs and weaker performance relative to the broader healthcare market. 

However, the concentrated biotech strategy may still attract more aggressive investors seeking targeted exposure to potential breakthroughs and high-growth opportunities within biotechnology. The trade-off is that investors must accept greater volatility, higher risk, and lower dividend income in exchange for the possibility of stronger gains during favourable biotech cycles.